Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
Prothenais eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars, including 100 million dollarsin upfront and near-term clinical milestone payments Novo Nordiskwill develop the phase 2 ready antibody PRX004 for the rare heart disease ATTR cardiomyopathy
PRX004 is a phase 2 ready anti-amyloid immunotherapy designed to deplete the amyloid deposits that are associated with the disease pathology of ATTR amyloidosis.
ATTR amyloidosis is a rare, progressive, and fatal disease characterised by the abnormal buildup of amyloid deposits composed of misfolded transthyretin protein in organs and tissues, most commonly the heart and/or nervous system.
Under the terms of the definitive purchase agreement,
“Today’s announcement is consistent with our commitment to create a better future for patients in critical need of new treatment options. We are confident that
“With its innovative amyloid-depleting mechanism, PRX004 has the potential to offer a novel treatment option for ATTR cardiomyopathy – an often fatal disease with significant unmet medical need,” said
PRX004 is an investigational humanised monoclonal antibody designed to deplete amyloid associated with disease pathology that underlies hereditary and wild type ATTR amyloidosis (hATTR and wtATTR, respectively), without affecting the native, normal tetrameric form of the protein. It is generally accepted that at the time of diagnosis, affected organs in ATTR patients contain extracellular amyloid deposits that cause organ dysfunction. PRX004 has been shown in preclinical studies to promote clearance of insoluble amyloid fibrils through antibody-mediated phagocytosis and inhibit amyloid formation. This depleter mechanism of action has the potential to provide benefit for ATTR patients at high risk for early mortality due to amyloid deposition in vital organs.
This press release contains forward-looking statements regarding the definitive purchase agreement and the development of PRX004, including the ability of
+1 650 837 8535, firstname.lastname@example.org
Novo Nordisk Media
Martin Havtorn Petersen
+45 3075 5246, email@example.com
Daniel Muusmann Bohsen
+45 3075 2175, firstname.lastname@example.org
Ann Søndermølle Rendbæk
+45 3075 2253, email@example.com
David Heiberg Landsted
+45 3077 6915, firstname.lastname@example.org
+1 848 213 3219, email@example.com
Source: Prothena Corporation plc